
Individual Patient Compassionate Use of Nirogacestat
Desmoid TumorNOTCH Gene Mutation Positive TumorsThis program is being offered on a patient by patient basis and will require company, Institutional Review Board/Independent Ethics Committee and Single Patient IND approval.

Intermediate-Size Patient Population Expanded Access Program for Intravenous Difelikefalin
Uremic PruritusThis is an intermediate-size patient population expanded access protocol for the use of intravenous (IV) difelikefalin for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients undergoing hemodialysis.

Expanded Access Protocol for Subjects Previously Treated With Gedatolisib in B2151009
Breast Neoplasm Malignant FemaleContinued access to treatment for subjects who continue benefit from therapy with gedatolisib in combination with palbociclib, and fulvestrant or letrozole.

Post-Trial Access for Guselkumab in Participants With Familial Adenomatous Polyposis
Adenomatous Polyposis ColiThe purpose of this post-trial access (PTA) program is to provide guselkumab to participants with Familial Adenomatous Polyposis (FAP) who are experiencing clinical benefit after completing 48 weeks of treatment in Study CNTO1959COR1001.

A Treatment Protocol to Support the Care of Children and Adolescents With Fibrosing Interstitial...
Lung DiseasesInterstitial (in Pediatric Populations)1 moreThis Expanded Access Program (EAP) is intended to facilitate the availability of OFEV® (nintedanib) to children and adolescents with chronic fibrosing interstitial lung disease (ILD) on top of current standard of care treatment and for whom no satisfactory authorized alternative therapy exists and who cannot participate in the ongoing 1199-0378 trial.

An Expanded Access Study to Assess Brensocatib for Participants With Non-Cystic Fibrosis Bronchiectasis...
Non-Cystic Fibrosis BronchiectasisThe purpose of this study is to allow early access to brensocatib for participants with non-cystic fibrosis bronchiectasis (NCFBE) who have successfully completed the INS1007301 ASPEN Clinical trial.

MAP to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera
Polycythemia VeraThe purpose of this Cohort Treatment Plan is to allow access to ruxolitinib for eligible patients diagnosed with Polycythemia Vera. The patient's Treating Physician should follow the suggested treatment guidelines and comply with all local health authority regulations.

Comparison of Clinical and Radiological Results of Using Only Screws and Plate Use in Latarjet Operation...
Shoulder DislocationRandomized controlled comparison of the clinical and radiological results of using only screws and plate use in latarjet surgery in shoulder instability

Expanded Access Program With Lenvatinib for the Treatment of Differentiated Thyroid Cancer in Brazil...
Thyroid CancerThis is an Expanded Access Program to make lenvatinib available to participants with radioiodine-refractory differentiated thyroid cancer in Brazil. Participants who have no other treatment options available, and who, in the opinion and clinical judgment of the treating physician, would benefit from treatment with lenvatinib will be enrolled. This is a multicenter, open-label program consisting of 2 phases: a 28-day pretreatment phase (including screening) and a treatment phase. Treatment will be provided as long as there is a clinical benefit based on tumor assessments performed according to the center's standard of care and the judgment of the participant's treating physician.

MLN8237 for a Subject With Adenocarcinoma of the Prostate
Prostate CancerTo allow a patient continued access to MLN8237